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Abstract 
Background: Diabetes mellitus is an important risk factor for cardiovascular disease. Different biomarkers have 
been investigated for the diagnosis of diabetes pathogenesis or its complications. There are also reports regarding an 
increased level of anti-HSP27 antibodies in atherogenesis. We aimed to evaluate serum anti-heat shock protein 27 
antibodies level in subjects with diabetes mellitus and undiagnosed individuals. Materials and Methods: This 
cross-sectional study was conducted on 6447 MASHAD study subjects, including four groups with diabetes mellitus 
(n=610), undiagnosed diabetes (n=162), impaired fasting glucose (IFG) (n=619) and normal (n=5056) subjects. 
Demographic and anthropometric data were obtained from all participants. Fasting serum glucose (FSG) and other 
parameters were measured. In-house enzyme-linked immune sorbent assay method was used for measuring Anti-
HSP27 antibodies levels. Results: There were significant differences in weight (p=0.034), body mass index, waist, 
and hip circumference, systolic and diastolic blood pressure, fasting serum glucose, lipid profile and high 
sensitive- C reactive protein (p<0.001) between four groups of diabetes mellitus, undiagnosed diabetes, impaired 
fasting glucose, and normal subjects. The serum anti-HSP27 antibody titer did not show a significant difference 
between studied groups. Conclusion: Serum antibody titers to HSP27 were not significantly different between four 
groups categorized based on their FSG levels in a large population.  
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Diabetes mellitus (DM) is characterized by 
hyperglycemia due to impaired secretion of insulin or 
insulin action [1]. DM is associated with premature 
cardiovascular disease (CVD) and microvascular 
disease [2].  
Some clinical and experimental documents 
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showed enhancement of oxidative stress (OS) 
resulting from reactive oxygen species (ROS) in type 
2 diabetes mellitus. The ROS can trigger chain 
reactions leading to the development and progression 
of T2DM macro and microvascular complications[3].  
Defective glucose homeostasis and insulin 
resistance in type 2 diabetes may be associated with 
an impairment in the expression and response of heat 
shock proteins [4].  
Heat shock proteins (HSP) are families of 
proteins that have essential functions and are present 
in all organisms [5, 6]. HSPs are expressed by cells 
and respond to environmental stresses such as 
exposure to free radicals, high temperatures, 
infections, and toxins [7]. HSPs have been classified 
into several families based on their molecular weight: 
Hsp10, Hsp27, Hsp40, Hsp60, Hsp70, Hsp90, and 
Hsp110 [8]. Hsp27 can be detected in most cells 
especially in reacting to cellular stress status like 
oxidative stress. HSP27 can reduce the concentration 
of ROS[9]. The expression level is indistinguishable 
or relatively low in some cells, however, the 
expression of Hsp27 is abundant in some other cells  
[10]. Serum Hsp27 concentrations appear to be a 
biomarker for cardiac ischemia [11]. It has been 
shown that serum Hsp27 concentration was found to 
be correlated with type 1 diabetes complications [12], 
although anti-HSP27 antibody titers were unrelated 
to serum Hsp27 antigen concentrations in type 1 
diabetic patients [13]. Anti-HSP27 antibody 
concentrations have been reported to be involved in 
the atherogenesis  [14], and are correlated with CVD 
risk factors such as age and hypertension [15].  In our 
study, we aimed to evaluate serum anti-HSP27 
antibody titers in the different groups based on 
glycemic status. 
Methods 
This cross-sectional study was conducted on 
subjects aged 35-64 years old who were categorized 
into four groups; diabetes mellitus (n=610), 
undiagnosed diabetes mellitus (n=162), impaired 
fasting glucose (IFG(n=619)  and a normal fasting 
serum glucose (n=5056).  Individuals were recruited 
as a part of the MASHAD Study cohort [16]. 
Exclusion criteria for all participants included 
pregnancy and breastfeeding women, subjects with 
cardiovascular disease, stroke, and systemic diseases. 
The research was approved by the Ethics Committee 
of Mashhad University of Medical Sciences. 
Individuals completed a written consent form for 
participation. Serum fasting glucose (FSG) was 
evaluated for the classification of subjects. Individuals 
with an FSG level above 126 (FSG≥126) were 
classified as having diabetes mellitus; those who had 
fasting blood glucose levels between 100–125 mg/dl 
were categorized in the IFG group [17]. Subjects 
whose diabetes have not been diagnosed previously, 
and were unaware of being diabetic, but whose FSG 
levels were ≥126 mg/dl in the screening tests termed 
undiagnosed diabetes [18].  
Anthropometric and demographic data 
collection. For all individuals, anthropometric 
parameters including weight, height, waist 
circumference, and hip circumference were measured 
using a standard protocol. Body mass index (BMI) 
was calculated using the formula, weight divided to 
height squared (m2), for each person. Weight and 
height measurements were performed using standard 
scales, to an accuracy of 0.1 kg and 0.1 cm 
respectively. Systolic and diastolic blood pressures 
were performed twice without stress, and the mean of 
the two pressures was recorded as the final blood 
pressure. 
Blood sampling and serum glucose level 
measurement. Blood samples were taken after fasting 
for at least 12 hours. Serum samples were obtained 
after centrifuging blood samples at 10,000 rpm for 15 
min, and the obtained serum was stored at -80 ° C 
until analysis. For all subjects, FSG concentration was 
measured after 12 hours of fasting. Fasting serum 
glucose concentrations were evaluated by routine 
enzymatic kit by Alycon auto analyzer (ABBOTT, 
Chicago, IL, USA). 
Serum anti-Hsp27 antibody concentration. 
Serum HSP27 antibody titers were measured using an 
enzyme-linked immune sorbent assay (ELISA). This 
method previously was described in detail [7]. 
Statistical analysis. All statistical analyses were 
performed using the SPSS version 16 software 
package. To evaluate the normality of data, we used 
the Kolmogorov-Smirnov test. Values were expressed 
as mean±SD or, in the case of non-normally 
distributed data, as median and inter-quartile range. To 
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illustrate the significant difference between two 
normal variables, independent t-test and between two 
non-normal quantitative variables from the Mann-
Whitney test and to evaluate abnormal variables in 
more than two groups of Kruskal-Wallis test and for 
standard variables, ANOVA was used. The level of 
statistical significance was set to p<0.05. 
Results 
Baseline demographic, anthropometric, and 
biochemical characteristics between participants in 
four groups, categorized base on the FSG level, are 
shown in Table 1. As expected, there were significant 
differences in weight (p=0.034), BMI, waist and hip 
circumference, SBP, DBP, FBS, triglyceride, 
cholesterol, LDL-C, and Hs-CRP between studied 
groups (p<0.001). The results showed that there was 
no significant difference in height, HDL-C, and BUN 
(p>0.05) (Table1). Serum HSP27 antibody levels did 
not show a significant difference between four groups 
of the study including subjects with diabetes mellitus, 
undiagnosed diabetes, IFG, and normal (p=0.513) 
(Fig.1.A). Also, there is not any significant difference 
in anti-HSP27 antibody concentration between men 
and women (undiagnosed: p=0.176, IFG: p=0.204, 
Diabetes: p=0.879 Normal: p=0.068) (Fig.1.B).  
Table1. Baseline clinical characteristic and Biochemical features of the study population 
Characteristics undiagnosed diabetes 
(162) 
IFG (619) Diabetes (610) Normal (5056) P-value 
Weight (kg) 74.73±13.39 74.92±13.35 73.06±12.25b 71.12±12.81abc <0.001 
Height (cm) 1.60±0.09 1.59±0.08 1.59 ±0.08 1.6 ± 0.91c <0.001 
BMI (kg/m2) 29.15±5.36 29.31±4.83 28.76±4.48 27.58 ±4.69abc <0.001 
WC (cm) 99.21±12.53 98.86±11.96 98.90±11.07 94.22±11.95abc <0.001 
HC (cm) 105.82±10.28 105.76±9.98 104.18±9.20b 103.35±9.20ab <0.001
SBP (mmHg) 126.61±18.90 128.42±20.76 128.81±19.77 119.97±17.62abc <0.001
DBP (mmHg) 81.21±11.32 82.41±12.08 81.26±11.12 78.38±11.03abc <0.001
FBS (mg/dl) 182.64±57.32 108.92±7.07a 164.68±74.55ab 79.15±9.76abc <0.001 
TC (mg/dl) 210.82±47.44 202.01±42.06a 199.86 ±45.03a 188.40±37.14abc <0.001 
TG (mg/dl) 154(98-224) 138(99-201)a 151(108-225)b 114(81-161)abc <0.001
HDL-C (mg/dl) 42.35±10.32 43.44±10.88 42.06±9.78b 42.85±9.81 0.024 
LDL-C (mg/dl) 126.52±41.91 122.84±37.11 120.26±37.95a 116.42±33.02abc <0.001 
hsCRP (mg/L) 2.59(1.41-6.16) 2.26(1.30-5.50) 2.33(1.30-4.74) 1.48(0.92-3.09)abc <0.001 
BUN (mg/dl) 12.37±4.38 13.05±4.23 13.15±4.31 12.99±4.20 0.224 
Cr (mg/dl) 0.86 ±0.28 0.85 ±0.23 0.87 ±0.30 0.86 ±0.24 0.570 
Data are shown as Mean ± SD for normal variables and interquartile range for non-normal variables. IFG impaired fasting glucose, BMI body mass 
index; WC waist circumferences; HC hip circumferences; SBP systolic blood pressure, DBP diastolic blood pressure, FSG fasting serum glucose, TC 
total cholesterol, TG triglycerides, HDL-C high-density lipoprotein, LDL-C low-density lipoprotein cholesterol, Hs-CRP high sensitivity C-reactive, 
BUN blood urea nitrogen, Cr creatinine. 
The covariance analysis was used to examine the difference in the mean of data. 
a: Differences between undiagnosed diabetes versus IFG, diabetes and normal groups 
b: Difference between IFG versus diabetes and normal groups 
c: Difference between diabetes and normal groups 
Tavana et al.                                               Serum anti-hsp27 antibodies concentration in diabetes mellitus; population … 
Vol 5, No 1,  Winter  2019 
15 
Multivariate regression for anti-HSP27 and 
diabetes status was done in different models (Table 
2).The effect of diabetes status on anti-HSP27 
levels assessed in the model 1 (unadjusted), model 
2 was adjusted for gender and age and model 3 was 
adjusted for gender, age, body mass index (BMI), 
smoking status and physical activity level (PAL) 
and has not been shown a significant association 
between anti-HSP27 level and diabetes in none of 
the models. 
Fig. 1. The concentration of anti-HSP-27 antibody; A: among the total population, B: according to gender. Data presented as median (inter-quartile 
range).  
     Table2. Multivariate regression for anti-HSP27 and Diabetes status. 
Variable    Model 1                                   
    
Odds (CI95%)                 P value                        
Model 2 
Odds (CI95%)             P value                                                                     
Model 3 
Odds(CI95%)            p value 
Undiagnosed 
diabetes 




1.31(0.88-1.97) 0.177 1.27(0.84-1.91) 0.25 1.15(0.76-1.73)              0.50  
Diabetes 1.16(0.77-1.76) 0.459 1.15(0.76-1.75) 0.49 1.12(0.73-1.70)               0.59 
   Model 1: unadjusted; Model 2: adjusted gender and age; Model 3: adjusted for and gender, age, body mass index (BMI), smoking status, and Physical 
Activity Level (PAL).The normal group was considered as a reference for the analysis. 
Discussion 
          The heat shock proteins are a family of proteins 
that have an antioxidant role and protect cells against 
various sources of stress. HSPs are primarily molecular 
chaperones that aid in protein folding, degrading of 
nonfunctional proteins, and preventing protein 
aggregation. A dual role is proposed for HSPs; an anti-
inflammatory role inside and a pro-inflammatory role 
outside the cell [19]. 
A characteristic feature of diabetes mellitus is 
uncontrolled oxidative stress and production of ROS 
leading to the development of microvascular and 
macrovascular complications such as nephropathy, 
retinopathy, and neuropathy. Therefore, the antioxidant 
functions of HSPs can prevent these complications. 
However, it has been recognized that diabetes can 
impair HSPs expression and synthesis which contributes 
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to complications commonly observed in diabetics and 
this creates a vicious cycle [14]. 
Several studies have discussed whether HSP27 
levels or Anti-HSP27 antibody titers could be served as 
a novel biomarker for diabetes complications [14]. 
A study by Habich et al. suggested that HSPs 
could be utilized in the development of novel 
therapeutic and diagnostic strategies for diabetes [20]. 
In this study, the serum anti-HSP27 antibody 
levels in patients with different stages of diabetes were 
analyzed using an enzyme-linked immune sorbent 
assay. The results indicated that no significant 
difference was found in anti-HPS27 levels between the 
four studied groups comprised of normal, diabetic, 
undiagnosed diabetes, and IFG patients. 
Additionally, the findings of this study suggested 
that there was no significant difference in anti-HPS27 
levels between females and males. 
In a 2008 study conducted by Gruden et al. in 
Italy, the association of sHSP27 levels with diabetes 
complications was investigated by ELISA and they 
concluded that sHSP27 levels could be used as a novel 
marker for diabetic neuropathy [12]. 
Burut et al. evaluated the Hsp27 antigen and anti-
HSP27 antibody (immunoglobulins M and G) levels of 
sera in individuals with various glycemic groups with or 
without cardiovascular events. They showed glucose 
intolerance patients with cardiovascular disease (CVD) 
had higher Hsp27 antigen titer compared glucose 
intolerance subject without CVD (p=0.03) and also 
normal glucose tolerance subjects with and without 
CVD (p=0.03 and p=0.02 respectively). There was a 
significant increased concentration of IgM anti-HSP27 
antibody between glucose intolerance patients with 
CVD comparison to normal glucose tolerance subjects 
without CVD group (p=0.02). Immunoglobulins G titer 
against Hsp27 antigen were higher in glucose 
intolerance patients with CVD in the glucose intolerance 
subjects without (p=0.06). They concluded Hsp27 
antigen and its antibody levels seem to be associated 
with CVD in glucose intolerance patients [14]. 
In a 2017 study which was performed on type 2 
diabetes subjects without and with microvascular 
complications, Plasma Hsp27 levels were measured by 
ELISA and their results indicated that patients with 
diabetic neuropathy (DNe) had higher levels of Hsp27, 
thereby it could be served as a potential biomarker of 
DNe [2]. 
In a study conducted by Burt et al. in 2009, the 
association of HSP27 antibody levels with micro- and 
macrovascular complications of type 1 diabetes was 
investigated as part of the cross-sectional analysis of the 
EURODIAB Prospective Complications Study using an 
in-house enzyme-linked immunosorbent assay. Their 
results showed that Anti-HSP27 antibody levels could 
not be used as a marker of vascular complications in 
type 1 diabetes which supports the results of the present 
study [13]. 
A similar study by Kargari et al. was carried out 
on 933 subjects with metabolic syndrome (MetS) to 
investigate the anti-Hsp27 antibody in their serum 
samples. Their results are in agreement with the present 
study because no difference in serum anti-HSP27 
concentrations was found between subjects with and 
without diabetes mellitus, metabolic syndrome, and 
gender [21]. 
In conclusion, our results revealed serum HSP27 
antibody levels did not show a significant difference 
between 4 groups were categorized based on their 
fasting serum glucose levels. we believe Anti-HSP27 
could not be an efficient method for the diagnosis of 
overt of latent diabetes. 
Conclusion 
The results of our investigation indicated that 
there was not a significant difference in serum anti-
HSP27 antibody titers among nondiabetic, diabetic, 
undiagnosed diabetes, and impaired fasting glucose 
subjects. 
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